1227210-33-4

Basic information

• Product Name: 5-Methyl-4,5,6,7-tetrahydro Pyrazolo[1,5-a]pyrazin-2-aMine
• Synonyms: 5-Methyl-4,5,6,7-tetrahydro Pyrazolo[1,5-a]pyrazin-2-aMine;4,5,6,7-tetrahydro-5-MethylPyrazolo[1,5-a]pyrazin-2-aMine
• CAS NO: 1227210-33-4
• Molecular Formula: C₇H₁₂N₄
• Molecular Weight: 152
• Mol File: 1227210-33-4.mol

Chemical Properties

• Boiling Point: 328.3±42.0 °C(Predicted)
• Appearance: /
• Density: 1.37±0.1 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 7.79±0.20(Predicted)
• CAS DataBase Reference: 5-Methyl-4,5,6,7-tetrahydro Pyrazolo[1,5-a]pyrazin-2-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Methyl-4,5,6,7-tetrahydro Pyrazolo[1,5-a]pyrazin-2-aMine(1227210-33-4)
• EPA Substance Registry System: 5-Methyl-4,5,6,7-tetrahydro Pyrazolo[1,5-a]pyrazin-2-aMine(1227210-33-4)

Safety Data

• Hazardous Substances Data: 1227210-33-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-Methyl-4,5,6,7-Tetrahydro pyrazolo[1,5-a]pyrazin-2-amine is used as a potential drug candidate for the development of new medications. Its unique chemical structure and properties make it a promising candidate for treating various medical conditions, although further research is required to fully understand its therapeutic potential and safety profile.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 5-Methyl-4,5,6,7-Tetrahydro pyrazolo[1,5-a]pyrazin-2-amine serves as a subject of interest for researchers. Its complex molecular structure and potential pharmaceutical properties provide a foundation for exploring new avenues in drug design and development, as well as understanding the underlying mechanisms of action for this compound.
Used in Biotechnology:
5-Methyl-4,5,6,7-Tetrahydro pyrazolo[1,5-a]pyrazin-2-amine may also find applications in the biotechnology industry. Its unique chemical properties could be harnessed for the development of novel biotechnological products or processes, such as targeted drug delivery systems or as a component in the design of new bioactive molecules.
Used in Chemical Sciences:
As a complex chemical compound, 5-Methyl-4,5,6,7-Tetrahydro pyrazolo[1,5-a]pyrazin-2-amine contributes to the broader field of chemical sciences. Its study can provide insights into the synthesis, reactivity, and properties of similar compounds, furthering our understanding of chemical reactions and the development of new synthetic routes for the production of pharmaceutically relevant molecules.

Upstream product

• 1227210-32-3 5-methyl-2-nitro-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine 
• 1408327-48-9 5-methyl-2-nitro-6,7-dihydropyrazolo[1,5-a]pyrazine-4(5H)-one 
• 1360057-00-6 methyl 1-(2-bromoethyl)-3-nitro-1H-pyrazole-5-carboxylate 
• 1227210-31-2 1-(2-bromoethyl)-5-(bromomethyl)-3-nitro-1H-pyrazole 
• 1227210-30-1 (1-(2-bromoethyl)-3-nitro-1H-pyrazole-5-yl)methanol 

Relevant articles and documents

Focal adhesion kinase inhibitor and use

The invention belongs to the field of medicines, relates to a focal adhesion kinase inhibitor and use, in particular relates to a novel focal adhesion kinase inhibitor compound, or stereoisomers, geometric isomers, tautomers, oxynitrides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof, further relates to the use of the compound and pharmaceutical compositions as medicines, in particular the use of the compound and pharmaceutical compositions in manufacture of medicines for treatment or prevention of cancer, pulmonary hypertension, and pathological angiogenesis-related diseases.

Discovery of highly potent and selective Bruton's tyrosine kinase inhibitors: Pyridazinone analogs with improved metabolic stability

BTK inhibitor GDC-0834 (1) was found to be rapidly metabolized in human studies, resulting in a suspension of clinical trials. The primary route of metabolism was through cleavage of the acyclic amide bond connecting the terminal tetrahydrobenzothiophene

SUBSTITUTED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF

The present disclosure relates to pyrimidine compounds of formula (I), their stereoisomers, tautomers, pharmaceutically acceptable salts, polymorphs, solvates, and hydrates thereof. The present disclosure also relates to process of preparation of these pyrimidine compounds, and to pharmaceutical compositions containing them. The compounds of the present disclosure are useful in the treatment, prevention or suppression of diseases and disorders mediated by epidermal growth factor receptor (EGFR) family kinases.

HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY

Heteroaryl pyridone and aza-pyridone compounds of Formula I are provided, where one or two of X, X, and Xare N, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I foranddiagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

INHIBITORS OF BRUTON'S TYROSINE KINASE

This application discloses compounds according to generic Formula I: wherein the variables are defined as described herein, and which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with

8-FLUOROPHTHALAZIN-1(2H)-ONE COMPOUNDS

8-Fluorophthalazin-1(2h)-one compounds of Formula II where one or two of X1, X2, and X3 are N, are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula II for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

BICYCLIC PIPERAZINE COMPOUNDS

Bicyclic piperazine compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

A concise synthesis of a tetrahydropyrazolopyrazine building block

A concise synthesis of a tetrahydropyrazolopyrazine building block is described. 5-Methyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazin-2-ylamine was prepared in three steps and 80% yield from 5-nitro-2H-pyrazole-3-carboxylic acid. This compound was then coupled with 4-bromo-6-chloro-2-methyl-2H- pyridazin-3-one in the presence of sodium tert-pentoxide to give the target product in 87% yield. The process was successfully scaled up to a multihundred gram scale.

PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF

Pyridazinone compounds of Formula (I) including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula (I) for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

PYRIDINONES/PYRAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF

Pyridone and pyrazinone compounds of Formula (I) including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.